@article{3164327,
    title = "Does patient education work in breast cancer? Final results from the
global CARIATIDE study",
    author = "Markopoulos, Christos and Neven, Patrick and Tanner, Minna and Marty, and Michael and Kreienberg, Rolf and Atkins, Louise and Franquet, Ann and and Gnant, Michael and Neciosup, Silvia and Tesarova, Petra and Barni, and Sandro and Deschamp, Veronique",
    journal = "Future oncology (London, England)",
    year = "2015",
    volume = "11",
    number = "2",
    pages = "205-217",
    publisher = "Future Medicine Ltd",
    doi = "10.2217/FON.14.179",
    keywords = "adherence; anastrozole; aromatase inhibitor; breast cancer; compliance;
letrozole; persistence",
    abstract = "Aim: To determine the impact of educational materials (EMs) on the
treatment compliance of postmenopausal women with hormone
receptor-positive (HR+) early-stage breast cancer. Patients & methods:
Patients (n = 2757) were randomized to standard aromatase inhibitors
(AI) alone (group A) or with EMs (group B) in a global, real-world
setting. Results: The 2-year results (n = 2242) showed EMs had no impact
on compliance (82 vs 82%, group A vs B), compliance with initial AI (82
vs 81%) or persistence (90 vs 88%), confirming the 1-year interim
analysis (n = 2567). Of the 2082 patients considered compliant at 1
year, 77% remained compliant at 2 years. Discontinuations (9%) were
mainly attributed to AI-related side effects (68% of discontinuations).
Exploratory analyses suggest a relationship between patient
characteristics and compliance behaviors. Conclusion: EMs do not improve
compliance in this patient population. Compliance and persistence are
complex end points influenced by multiple variables. Side effects were
the main reasons for discontinuations."
}